Searched for
CYTOSORB
Fresh tailwinds emerge as government comes in again with intent: 7 pharma stocks with upside potential of up to 36%- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of more than 26% in 1 year
- Ignore noise on the street, stick to basics: 5 stocks from different sectors with an upside potential of up to 38%
- Getting back into shape? 6 Indian pharma stocks with upside potential of up to 41%The year 2024, started with a correction in nifty, but one set of stocks which were able to outperform were pharma stocks. While it might a...04 Jan, 2024, 02.09 PM IST
- These largecaps have ‘strong buy’ & ‘buy’ recos and upside potential of more than 20%In the last few weeks, the range in which the nifty had been moving has become broader as the volatility has increased both due to internat...14 Nov, 2023, 11.46 AM IST
- These largecaps have ‘strong buy’ & ‘buy’ recos and upside scope of over 20%As the market moves from clearly bullish mode to volatile mode with a bearish bias, there will be readjustment in valuation across markets....07 Nov, 2023, 01.02 PM IST
- These largecaps have ‘strong buy’ & ‘buy’ recos and upside potential of more than 20%While the correction has been going on in the market since the middle of July, it is only on days like Monday where everyone on the street ...25 Oct, 2023, 11.46 AM IST
- Nifty healthcare index stocks analysts suggest buying have potential upside of more than 19%Except for a pocket in which demand for covid drugs led to sharp surge in pharma stocks, the pharma sector had been under pressure for a lo...10 May, 2023, 01.13 PM IST
- These largecaps have ‘Strong Buy’ & ‘Buy’ reco and upside potential of more than 25%As the NIFTY and broader market recovers, analysts are bullish on select large cap stock. Making to the list are a host of companies from d...02 May, 2023, 01.12 PM IST
- Should you stick to largecaps amid volatile Nifty? These 4 stocks have up to 30% upside scopeAs volatility increases, the focus in the market is shifting to stocks which are considered as relatively defensive. These stocks tend to f...09 Feb, 2023, 05.54 PM IST
- A consistent wealth creator among 11 stocks that have an upside potential of over 25%As the market witnesses volatile movement there are few large cap stocks which are still finding favor with analysts. After the recent corr...17 Jan, 2023, 11.25 AM IST
- Biocon Biologics gets licence from Adagio Therapeutics for antibody treatment of COVID-19"ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is in global clinical development ...26 Jul, 2021, 09.29 PM IST
- Billion dollar target for biologics biz by FY22 unrealistic, but we would soon return to high growth trajectory: Kiran Mazumdar Shaw“There is a marginal decline in biosimilar segment but we expect to see the business pick up in Q1 of FY22.”29 Apr, 2021, 05.03 PM IST
- Biocon Q4 results: Net profit grows 105% on strong biosimilar business growthFor the fiscal year 2020-21, Biocon reported a 1 per cent decline in net profit to Rs 740 crore; while revenue grew 14 per cent to Rs 7360 ...29 Apr, 2021, 08.18 AM IST
- Biocon Q2 results: Net profit drops 22% on higher R&D cost; revenue jumps 10%Biocon reported a 10% rise in total revenue to Rs 1,760 crore driven by overall growth in generics, biosimilar and research services busine...23 Oct, 2020, 09.57 AM IST
- Biosimilar drugs can help us reach $1 billion target soon: Christiane Hamacher, CEO, Biocon BiologicsIt is all about reaching our $1billion revenue target by FY22 and to reach 5 million patients by end of 2022, says Christiane Hamacher.16 Jun, 2020, 11.03 AM IST
- Biocon gets DCGI nod for device to treat critical COVID-19 patientsThe company has been granted licence for emergency use of CytoSorb, an extracorporeal blood purification device CytoSorb to reduce pro-infl...27 May, 2020, 12.57 PM IST
- Looking at 'repurposing' drugs: BioconWe are working to repurpose our novel monoclonal antibody Itolizumab (used in psoriasis) to treat complications caused by Covid-19 infectio...02 May, 2020, 10.42 AM IST
- Biocon, CytoSorbents expand pact to treat body inflammationCompanies have expanded the scope of their strategic partnership for cytokine reduction therapy, CytoSorb, to treat patients experiencing s...03 Nov, 2014, 07.13 PM IST
- Biocon inks pact with US firm for sepsis treatment therapyKiran Mazumdar Shaw said the partnership will enable the company to address the huge unmet need of sepsis management in India and emerging ...14 Sep, 2013, 05.05 AM IST
Load More
